DKK1
Phase 1Biologic
DKK1 is one of 13 biologic programs targeting Monoclonal Gammopathy. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Monoclonal Gammopathy
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Darzalex
Johnson & JohnsonPhase 2
Brukinsa
BBeOne Medicines
Phase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Linvoseltamab
RegeneronPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Monoclonal Gammopathy1 trial
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Withdrawn·—·Phase 1·NCT03591614
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DKK1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCase Comprehensive Cancer Center